19. Statins in Portal Hypertension

  1. Roberto de Franchis MD, AGAF Professor of Gastroenterology Head
  1. Juan G Abraldes MD1,
  2. Vincenzo La Mura MD1,
  3. Jaime Bosch MD2

Published Online: 17 NOV 2010

DOI: 10.1002/9781444393989.ch19

Book Title

Portal Hypertension V: Proceedings of the Fifth Baveno International Consensus Workshop, Fifth Edition

Portal Hypertension V: Proceedings of the Fifth Baveno International Consensus Workshop, Fifth Edition

Additional Information

How to Cite

Abraldes, J. G., La Mura, V. and Bosch, J. (2011) Statins in Portal Hypertension, in Portal Hypertension V: Proceedings of the Fifth Baveno International Consensus Workshop, Fifth Edition (ed R. de Franchis), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444393989.ch19

Editor Information

  1. Department of Medical Sciences, University of Milan, and Gastroenterology 3 Unit, IRCCS Ca' Granda Ospedale Maggiore Policlinico Mangiagalli and Regina Elena Foundation, Milan, Italy

Author Information

  1. 1

    Hepatic Haemodynamic Laboratory, Liver Unit, Hospital Clinic, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

  2. 2

    Hepatic Haemodynamic Laboratory, Liver Unit, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain

Publication History

  1. Published Online: 17 NOV 2010
  2. Published Print: 14 JAN 2011

ISBN Information

Print ISBN: 9781444334494

Online ISBN: 9781444393989

SEARCH

CHAPTER TOOLS

Get PDF (559K)

Keywords:

  • a look into the future - new treatments on the horizon;
  • statins in portal hypertension;
  • liver cirrhosis, primary factors - portal hypertension, increasing resistance to portal blood flow;
  • ideal drug for portal hypertension - reducing portal pressure, decreasing intrahepatic vascular resistance;
  • use of statins in cirrhosis - expression of endothelial nitric oxide synthase (eNOS) and its activity at posttranslational level;
  • potential mechanisms, mediating - decrease in hepatic resistance by statins;
  • statins and liver circulation;
  • common bile duct ligation (CBDL) model;
  • statins in patients with cirrhosis;
  • potential of statins in patients with cirrhosis in RCTs - with clinical endpoints

Summary

This chapter contains sections titled:

  • The need for new drugs in portal hypertension

  • Rationale for the use of statins in cirrhosis

  • Statins in patients with cirrhosis

  • Other potential benefits of statins in cirrhosis

  • Future perspectives

  • References

Get PDF (559K)